Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Other Non-Current Liabilities (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Other Non-Current Liabilities data on record, last reported at $41.3 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 316.16% year-over-year to $41.3 million; the TTM value through Sep 2025 reached $41.3 million, up 316.16%, while the annual FY2023 figure was $4.9 million, 6205.19% up from the prior year.
  • Other Non-Current Liabilities reached $41.3 million in Q3 2025 per MBRX's latest filing, up from $17.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $41.3 million in Q3 2025 and bottomed at $1000.0 in Q3 2023.
  • Average Other Non-Current Liabilities over 5 years is $5.7 million, with a median of $1.7 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 99.69% in 2023, then skyrocketed 993100.0% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $1.4 million in 2021, then tumbled by 94.55% to $77000.0 in 2022, then skyrocketed by 6205.19% to $4.9 million in 2023, then soared by 104.57% to $9.9 million in 2024, then surged by 316.16% to $41.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $41.3 million in Q3 2025, $17.0 million in Q2 2025, and $9.9 million in Q3 2024.